SNTI Stock Forecast & Price Target

Senti Biosciences is a clinical stage biotechnology company that has a competitive profile in the cell and gene therapy space, with its lead candidate, SENTI-202, demonstrating a favorable CR/CRh rate of 39% among evaluable patients with relapsed or refractory AML. This data provides encouraging efficacy and durability signals for a broad AML population, and the company has also received RMAT designation from the FDA. However, there are clinical risks and uncertainties in the adoptive cell therapy field that could impact the achievement of the company's price target of $11.

Senti Biosciences is a clinical-stage biotechnology company leveraging its synthetic biology platforms to engineer cell and gene therapies carrying gene circuits designed to address challenges of current genetic medicines. With their small market share and limited visibility on their pivotal study initiation within 2026, we foresee financing risks and low probability of success, resulting in a negative outlook on the company's stock. Additionally, a lack of precedent in the CAR-NK cell therapy space and potential competition from other modalities could limit the commercial potential of Senti's products, potentially leading to downward revisions of our price target.